Diligence memo · auto-generated · as of July 2, 2026

PhotonPharma, Inc.

PhotonPharma, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

PhotonPharma, Inc. operates in Biotechnology, based in FORT COLLINS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

PhotonPharma, Inc. has raised $3.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.9M on 2022-01-31.

Most recent recorded round closed around 2024-05-07.

Valuation (modeled)modeled

Provath models PhotonPharma, Inc. at approximately $1.8M (range $252K–$5.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.13× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 14 months.

Last raise 2.2 yr ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round was 8.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 35% of Biotechnology peers (4293 compared).

Modeled value ranks above 5% of those peers.

Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.